

# Intravitreal Triamcinolone with Transpupillary Thermal Therapy (TTT) for Subfoveal Choroidal Neovascularization in Age Related Macular Degeneration

<b>Submission date</b> 09/05/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 16/05/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 18/02/2008	<b>Condition category</b> Eye Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Ricardo Agurto-Rivera

**Contact details**  
Exequiel Fernández n° 920  
Casa F  
Ñuñoa  
Santiago  
Chile  
+56 8 5021968  
ricardo\_agurto@yahoo.com

## Additional identifiers

**Protocol serial number**  
N/A

## Study information

## Scientific Title

### Study objectives

TTT plus intravitreal triamcinolone are effective treatment for choroidal neovascularization and are better than TTT alone.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration

### Study design

Randomised controlled trial

### Primary study design

Interventional

### Study type(s)

Treatment

### Health condition(s) or problem(s) studied

Age-Related Macular Degeneration (ARMD) not available for current therapies

### Interventions

Complete ophthalmologic examination, treatment with TTT alone compared with treatment with TTT plus intravitreal Triamcinolone. Ophthalmologic control to verify closure of CNV or re-treatment.

### Intervention Type

Drug

### Phase

Not Specified

### Drug/device/biological/vaccine name(s)

Triamcinolone

### Primary outcome(s)

Preservation of visual acuity

### Key secondary outcome(s)

Closure of CNV, OCT characteristics

### Completion date

28/02/2006

## Eligibility

**Key inclusion criteria**

Patients with severe ARMD (choroidal neovascularization [CNV]) that could not be treated with photodynamic therapy (PDT) because of bad prognosis or economical reasons.

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Not Specified

**Sex**

Not Specified

**Key exclusion criteria**

1. Any patient that has indication for PDT and has the economical means to get this therapy
2. Media opacity
3. Previous treatment for CNV

**Date of first enrolment**

01/02/2004

**Date of final enrolment**

28/02/2006

**Locations****Countries of recruitment**

Chile

Mexico

**Study participating centre**

Exequiel Fernández n° 920

Santiago

Chile

**Sponsor information****Organisation**

Association to Avoid Blindness (Asociación Para Evitar La Ceguera) (APEC) (Mexico)

ROR

https://ror.org/03sgfhr82

## Funder(s)

### Funder type

Charity

### Funder Name

Association to Avoid Blindness (Asociación Para Evitar La Ceguera) (APEC) (Mexico)

## Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	25/11/2005		Yes	No